Cover Image

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Show other versions (1)

Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower single dose of c...

Full description

Saved in:
Bibliographic Details
Main Authors: Kriegsmann, Katharina (Author) , Schöning, Tilman (Author) , Schwarzbich, Mark-Alexander (Author) , Cremer, Martin (Author) , Dittrich, Tobias (Author) , Ho, Anthony Dick (Author) , Witzens-Harig, Mathias (Author)
Format: Article (Journal)
Language:English
Published: 11 April 2016
In: BMC cancer
Year: 2016, Volume: 16
ISSN:1471-2407
DOI:10.1186/s12885-016-2289-y
Online Access:Verlag, Volltext: https://doi.org/10.1186/s12885-016-2289-y
Get full text
Author Notes:K. Lisenko, F. McClanahan, T. Schöning, M.A. Schwarzbich, M. Cremer, T. Dittrich, A. D. Ho and M. Witzens-Harig
Search Result 1
Cover Image

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma by Kriegsmann, Katharina (Author) , Schöning, Tilman (Author) , Schwarzbich, Mark-Alexander (Author) , Cremer, Martin (Author) , Dittrich, Tobias (Author) , Ho, Anthony Dick (Author) , Witzens-Harig, Mathias (Author) ,

BioMed Central; Springer 11 April 2016

Get full text
Article (Journal) Book/Monograph Online Resource

Saved in:
Show all versions (2)

Similar Items